Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F02%3A00003703" target="_blank" >RIV/00216208:11120/02:00003703 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.ima.org.il/imaj/ar02apr-8.pdf" target="_blank" >http://www.ima.org.il/imaj/ar02apr-8.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases

Popis výsledku v původním jazyce

Intractable forms of autoimmune diseases follow a rapid course, with a significantly shortened life. expectancy sometimes comparable to that of malignant diseases. Immunoablative therapy; including high dose cytotoxic agents and hematopoietic autologousstem-cell rescue, was recently introduced as an aggressive approach to treat autoimmune diseases that-have a rapid course and are resistant to conventional therapy. The most frequent indication for this type of treatment is multiple sclerosis, seconded by systemic sclerosis. The results of immunoablative treatment with documented responses in both diseases are encouraging. The data are mature enough to begin comparative randomized studies of immunoablative versus conventional treatment to validate the benefit, of the aggressive approach. A randomized trial involving SSc was recently launched (ASTIS) and a trial involving MS is in preparation: Considerably less experience with; immunoablative treatment has, been gained in systemic lupus

Název v anglickém jazyce

Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases

Popis výsledku anglicky

Intractable forms of autoimmune diseases follow a rapid course, with a significantly shortened life. expectancy sometimes comparable to that of malignant diseases. Immunoablative therapy; including high dose cytotoxic agents and hematopoietic autologousstem-cell rescue, was recently introduced as an aggressive approach to treat autoimmune diseases that-have a rapid course and are resistant to conventional therapy. The most frequent indication for this type of treatment is multiple sclerosis, seconded by systemic sclerosis. The results of immunoablative treatment with documented responses in both diseases are encouraging. The data are mature enough to begin comparative randomized studies of immunoablative versus conventional treatment to validate the benefit, of the aggressive approach. A randomized trial involving SSc was recently launched (ASTIS) and a trial involving MS is in preparation: Considerably less experience with; immunoablative treatment has, been gained in systemic lupus

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2002

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Israel Medical Association Journal

ISSN

1565-1088

e-ISSN

—

Svazek periodika

4

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

IL - Stát Izrael

Počet stran výsledku

4

Strana od-do

268-271

Kód UT WoS článku

000182574000008

EID výsledku v databázi Scopus

—